Growth (healthcare-only) fund research profile
Quadria Capital is an Asia-focused healthcare private-equity firm investing in regional healthcare leaders through growth, significant-minority and majority positions. Its India activity spans healthcare delivery, life sciences, medical devices and associated services.
At a glance
Research profile
Open a section to inspect the evidence. The first view starts with the investment point of view; the rest stays quiet until you need it.
Investment lens
Quadria Capital uses a growth (healthcare-only) approach across Hospitals, pharma, diagnostics, medtech.
Current evidence
Quadria closed its oversubscribed Fund III at US$1.07 billion in May 2025 and said the fund was already nearly 40% deployed, including Aragen Life Sciences, NephroPlus and Maxivision. Its 2025–26 review also documents the Akums IPO partial exit and continued growth at Encube and Maxivision.
Strategy
Growth (healthcare-only)
Sector focus
Hospitals, pharma, diagnostics, medtech
AIF structure context
Indian private equity, growth, buyout and many real-asset strategies are commonly structured as Category II AIFs. Verify the specific vehicle and registration before investing.
Current signal
Quadria closed its oversubscribed Fund III at US$1.07 billion in May 2025 and said the fund was already nearly 40% deployed, including Aragen Life Sciences, NephroPlus and Maxivision. Its 2025–26 review also documents the Akums IPO partial exit and continued growth at Encube and Maxivision.
Investor questions
Quadria Capital is covered in Rupeia's private equity research universe. The current public record describes the strategy as Growth (healthcare-only), with a sector focus of Hospitals, pharma, diagnostics, medtech. The profile should be read with the linked source trail and Typical route: Category II AIF context.
The profile displays only company or asset names attributable to Quadria Capital in the reviewed public sources: Aragen Life Sciences, NephroPlus, Maxivision Eye Hospitals, Akums Drugs and Pharmaceuticals, Encube Ethicals, Straits Orthopaedics, MediBuddy, Qure.ai. It does not represent a complete current portfolio unless the manager has published one.
Quadria reported Fund I and II outcomes including 1.8x and 4.2x gross cash returns on named exits, while its 2024–25 review describes the exit of India’s Concord Biotech. Mint reported a Fund III objective of nearly 1.5x DPI by early 2027; these are reported outcomes, not audited net fund performance. These signals are not a substitute for fund- and vintage-specific net performance, realised distributions and audited or administrator-supported reporting.
Public fund size: Fund III closed at US$1.07B, with approximately US$1.3B including anticipated co-investment capacity; the manager reports over US$4B AUM across Asia and 27 investments.. Public terms or access information: Significant-minority and majority investments in healthcare businesses, with dedicated operating expertise and co-investment capacity; India-only cheque and reserve policy are not separately disclosed.. Current fees, minimum commitment and availability must be confirmed for the exact named vehicle in its fund documents.
The current source record names Abrar Mir, Amit Varma. Verify current roles, departures, attribution and key-person provisions before relying on the team history for a new commitment.
Review entry valuation, leverage, governance rights, concentration, execution of the value-creation plan and exit timing. The current open diligence point is: India-versus-Southeast Asia allocation and fund-level returns remain not publicly disclosed; the mandate is Asia healthcare private equity..
2025-05-27: Quadria closed its oversubscribed Fund III at US$1.07 billion in May 2025 and said the fund was already nearly 40% deployed, including Aragen Life Sciences, NephroPlus and Maxivision. Its 2025–26 review also documents the Akums IPO partial exit and continued growth at Encube and Maxivision.
Next step
Share the allocation question, ticket size, liquidity constraints and existing exposure. Rupeia can determine whether this profile needs a deeper decision-support brief.